Syphilis Clinical Trial
Official title:
Clinical Trial Evaluating the Clinical Efficacy of Cefixime for Treatment of Early Syphilis
The goal of the study is to evaluate the efficacy of oral cefixime as an alternative treatment for syphilis infection. One hundred adult patients (≥18 years old) with syphilis infection (positive Treponema Pallidum Particle Agglutination assay and RPR titer ≥ 1/8) will be recruited. Participants will be randomized (1:1) to receive either the standard of care Penicillin or Cefixime. During the study, participants will visit the clinic up to 5 times; at baseline visit, at 3, 6, 12 months after treatment initiation. Participants of the cefixime group will be required to visit the clinic 14 days after treatment initiation. In each visit, participants will be asked about current symptoms and do laboratory tests for syphilis (RPR). Subjects who have a 4-fold decrease (from study entry RPR) in RPR titers from baseline at 6 months will be considered a positive treatment response.
Syphilis is a major issue worldwide causing 5.6 million new cases of syphilis worldwide, of which over 900,000 are pregnant women. It is also responsible for congenital infections causing fetal loss or stillbirth or, in a live-born infant, neonatal death, prematurity and low birth weight. Penicillin is the currently used treatment. However, lack of penicillin and alternatives to treatment often hinder treatment and prevention efforts. Cefixime is an FDA-approved, orally administered third-generation cephalosporin that is currently used for the treatment of a wide range of infections, including urinary tract infections. Our goal is to evaluate the efficacy and safety of oral cefixime as an alternative treatment for syphilis infection. One hundred adult patients (≥18 years old) with syphilis infection will be recruited. Eligible participants will have laboratory-confirmed syphilis infection with a positive Treponema pallidum Particle Agglutination (TPPA) assay and RPR (Rapid Plasma Reagin ) titer ≥ 1/8. Participants will be randomized (1:1) to receive either the standard of care Penicillin or Cefixime. During the study, participants will visit the clinic 5 times; at baseline visit, demographic, clinical information and laboratory test results for syphilis will be recorded and treatment will start. Depending on the study group, the treatment plan will be oral Cefixime 400mg, twice per day for ten consecutive days or one dose of intramuscular Penicillin. Patients will be required to visit the clinic two weeks after treatment initiation to verify adverse effects. Follow up visits will occur at 3, 6 and 12 months after treatment initiation. In each visit, participants will be asked about current symptoms, interval sexual history, concomitant antibiotic use and possible adverse reactions. Subjects will also have a venipuncture blood specimen collected for syphilis testing (RPR). Subjects who have a 4-fold decrease (from study entry RPR) in RPR titers from baseline at 6 months will be considered a positive treatment response. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05548426 -
Linezolid for Syphilis Pilot Study
|
Phase 2 | |
Completed |
NCT02191527 -
Evaluating the Effectiveness of Point-of-care Diagnostic Technologies in MCH Services in Mozambique
|
N/A | |
Completed |
NCT01439503 -
Safer Sex Program for Young African-American Men
|
Phase 2 | |
Completed |
NCT02257658 -
Efficacy of Doxycycline Prophylaxis to Reduce Syphilis in High-Risk, HIV-Positive MSM
|
N/A | |
Terminated |
NCT01540227 -
Penicillin Therapeutic Drug Monitoring in the Treatment of Infectious Syphilis.
|
||
Completed |
NCT02611765 -
Syphilis Response to Higher Penicillin Dosage: The 2.4 Versus 7.2 Study
|
Phase 4 | |
Not yet recruiting |
NCT06428643 -
A Seek, Test, and Treat Intervention to Reduce Chlamydia Trachomatis Disparities
|
N/A | |
Completed |
NCT03709862 -
Global Syphilis Sequencing
|
||
Completed |
NCT03637660 -
Phase 4 Comparative Trial of Benzathine Penicillin G for Treatment of Early Syphilis in Subjects With or Without HIV Infection
|
Phase 4 | |
Active, not recruiting |
NCT03310424 -
Transcriptomic and Next Generation Sequencing Approaches to Infection With Treponema Pallidum
|
||
Completed |
NCT00207506 -
Lay Health Advisors for Sexually Transmitted Disease Prevention
|
Phase 1/Phase 2 | |
Completed |
NCT00213018 -
Safety, Acceptability and Preliminary Effectiveness of Carraguard™ (PC-515) in Preventing HIV/STI Transmission
|
Phase 2 | |
Recruiting |
NCT06059443 -
mLab App Plus: A Randomized Controlled Trial of a Mobile Health (mHealth) Intervention
|
N/A | |
Completed |
NCT04480749 -
Syphilis Self-testing to Expand Test Uptake Among Men Who Have Sex With Men (SST)
|
Phase 4 | |
Not yet recruiting |
NCT06058286 -
MENJAGA: Continuous Quality Improvement for Antenatal HIV, Syphilis and Hepatitis B Testing in Indonesia
|
N/A | |
Active, not recruiting |
NCT03980223 -
Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men
|
Phase 4 | |
Completed |
NCT01465607 -
Implementation of an Efficacious Intervention for High Risk Women in Mexico
|
N/A | |
Completed |
NCT00553111 -
Video Tool to Promote Knowledge of Syphilis as Facilitator of HIV Transmission
|
N/A | |
Active, not recruiting |
NCT06367621 -
Retrospective Study of iStatis Syphilis Ab Test (POC)
|
||
Completed |
NCT02445846 -
Dual Rapid HIV & Syphilis Tests in Zambia
|
N/A |